Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?

Investors looking for stocks that can make dramatic gains fairly quickly got what they wanted from CRISPR Therapeutics (CRSP -0.34%) this year. The stock is up more than 60% in 2023 after the company earned Food and Drug Administration (FDA) approval for its first treatment, Casgevy.CRISPR Therapeutics is transitioning into a commercial-stage company. But new drug launches can be unpredictable, and Casgevy, which it developed with partner Vertex Pharmaceuticals (VRTX 0.10%), will be breaking a lot of new gr ...